Northern Trust Corp Has $15.10 Million Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Northern Trust Corp lifted its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 6.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 597,605 shares of the biopharmaceutical company's stock after acquiring an additional 34,885 shares during the period. Northern Trust Corp owned 0.90% of Celldex Therapeutics worth $15,101,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Invesco Ltd. lifted its holdings in Celldex Therapeutics by 2.1% in the fourth quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company's stock valued at $1,064,000 after acquiring an additional 871 shares during the period. EverSource Wealth Advisors LLC increased its position in shares of Celldex Therapeutics by 215.7% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 878 shares in the last quarter. Swiss National Bank increased its position in shares of Celldex Therapeutics by 1.2% in the fourth quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company's stock valued at $2,964,000 after buying an additional 1,400 shares in the last quarter. KBC Group NV increased its position in shares of Celldex Therapeutics by 79.1% in the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock valued at $94,000 after buying an additional 1,647 shares in the last quarter. Finally, MetLife Investment Management LLC increased its position in shares of Celldex Therapeutics by 6.1% in the fourth quarter. MetLife Investment Management LLC now owns 39,620 shares of the biopharmaceutical company's stock valued at $1,001,000 after buying an additional 2,288 shares in the last quarter.

Celldex Therapeutics Stock Down 2.2%

CLDX stock traded down $0.45 during midday trading on Wednesday, hitting $20.05. 26,567 shares of the company traded hands, compared to its average volume of 890,147. The business has a 50 day simple moving average of $18.91 and a 200-day simple moving average of $22.51. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of -7.80 and a beta of 1.39. Celldex Therapeutics, Inc. has a twelve month low of $14.40 and a twelve month high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). The company had revenue of $0.70 million during the quarter, compared to analyst estimates of $1.08 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. Equities research analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on CLDX shares. HC Wainwright reiterated a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday, May 6th. UBS Group cut their target price on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. The Goldman Sachs Group lowered their price objective on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. Canaccord Genuity Group initiated coverage on Celldex Therapeutics in a research note on Monday, April 28th. They issued a "buy" rating and a $64.00 price target for the company. Finally, Morgan Stanley reduced their price objective on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $53.90.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.